Home » Newsletters » BioWorld Science

BioWorld Science

June 23, 2021

View Archived Issues

CaroGen to advance development of its novel immunotherapy candidate

First patients enrolled in IMPROVE-DiCE study of IMB-101

Neurona Therapeutics to advance its neural network-rebalancing cell therapies

Positive topline data from phase I study of emricasan in patients with mild symptomatic COVID-19

Augmenta and TFF select first lead monoclonal antibody candidate against COVID-19

Phase I dose-escalation data presented for BI-907828 in advanced solid tumors

Taiho Pharmaceutical and Astex Therapeutics patent GTPase KRAS inhibitors

Theravance Biopharma presents JAK3 inhibitors

Captor Therapeutics identifies new CRBN-targeting compounds

Lupin synthesizes new SOS1 inhibitors

NP-G2-044 shows safety and preliminary antitumor activity in phase I study

DTx Pharma presents new compounds for DMD

POLQ is next target for DNA damage response

New generation of antifungal membrane active peptides from combinatorial library screening

Gemini reports data from ongoing phase IIa study on GEM-103 in GA secondary to dry AMD

Sosei opens phase I trial of CGRP receptor antagonist HTL-0022562

RASSF1A and PRSS21 are diagnostic markers of TGCT

Tiziana prepares for phase II trial of intranasal foralumab in severe COVID-19

Keros reports preliminary phase II data on KER-050 for MDS

miR-126-3p has potential for diagnosing Parkinson's disease

New phase I trial studies DCP-001 in high-grade serous ovarian cancer

uniQure agrees to acquire Corlieve Therapeutics and lead gene therapy program

New phase I trial explores use of TLX250-CDx in bladder cancer

Aleta and Cancer Research UK collaborate on first-in-human study of ALETA-001

FDA clears IND for clinical evaluation of CLBS-201 for diabetic kidney disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...